Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. de Angelis · SciRah

Researcher profile · Semantic Scholar

C. de Angelis

Share profile

C. de Angelis — researcher profile on SciRah

h-index: 37
Works: 221
Citations: 6,179

Most-cited papers

PARP Inhibitors for Breast Cancer Treatment: A Review.
S. Morganti, Antonio Marra, C. de Angelis, A. Toss +11 more
2024JAMA Oncology89 citations Open access
Semantic Scholar
Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study.
M. Lambertini, E. Blondeaux, E. Agostinetto, A. Hamy +50 more
2023Journal of the American Medical Association (JAMA)64 citations Open access
Semantic Scholar
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?
C. Corti, C. de Angelis, G. Bianchini, L. Malorni +6 more
2023Cancer Treatment Reviews59 citations
Semantic Scholar
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
S. Pignata, G. Scambia, C. Schettino, L. Arenare +26 more
2023The Lancet Oncology47 citations
Semantic Scholar
Germline TP53 pathogenic variants and breast cancer: A narrative review.
E. Blondeaux, L. Arecco, K. Punie, R. Graffeo +11 more
2023Cancer Treatment Reviews41 citations Open access
Semantic Scholar
Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor–positive Breast Cancer
C. Guarducci, A. Nardone, D. Russo, Zsuzsanna Nagy +27 more
2024Clinical Cancer Research34 citations Open access
Semantic Scholar
Hereditary breast and ovarian cancer: from genes to molecular targeted therapies
G. Ponti, C. de Angelis, R. Ponti, Linda Pongetti +4 more
2023Critical reviews in clinical laboratory sciences34 citations
Semantic Scholar
EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer.
S. Belli, D. Esposito, C. M. Ascione, Francesca Messina +5 more
2024Cancer Letters31 citations Open access
Semantic Scholar
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies
M. Lambertini, E. Blondeaux, G. Bisagni, S. Mura +25 more
2023EClinicalMedicine31 citations Open access
Semantic Scholar
In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study
F. Pepe, E. Guerini-Rocco, M. Fassan, Nicola Fusco +16 more
2023Journal of Clinical Pathology29 citations Open access
Semantic Scholar
New steps on an old path: Novel estrogen receptor inhibitors in breast cancer.
M. Pagliuca, Marco Donato, A. L. d'Amato, M. Rosanova +10 more
2022Critical reviews in oncology/hematology26 citations Open access
Semantic Scholar
Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial.
C. Roma, R. Esposito Abate, A. Sacco, D. Califano +18 more
2024European Journal of Cancer24 citations
Semantic Scholar
High FOXA1 Levels Induce ER Transcriptional Reprogramming and Promote a Pro-metastatic Secretome and Metastasis in Endocrine-resistant Breast Cancer
Xiaoyong Fu, Resel Pereira, C. Liu, C. de Angelis +18 more
2023Cell Reports23 citations Open access
Semantic Scholar
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2–Negative Metastatic Breast Cancer
P. B. Berton Giachetti, S. Morganti, S. Gandini, Fabiola Giudici +28 more
2025JAMA Network Open21 citations Open access
Semantic Scholar
Analysis of circulating extracellular vesicle derived microRNAs in breast cancer patients with obesity: a potential role for Let-7a
I. Barone, L. Gelsomino, F. Accattatis, F. Giordano +11 more
2023Journal of Translational Medicine21 citations Open access
Semantic Scholar
Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer
S. Belli, D. Esposito, Alessandra Allotta, A. Servetto +10 more
2023npj Breast Cancer21 citations Open access
Semantic Scholar
Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging Strategies.
F. Giugliano, C. de Angelis, B. Pistilli, G. Viale +9 more
2025Cancer Treatment Reviews20 citations Open access
Semantic Scholar
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
Anran Chen, Beom-Jun Kim, Aparna Mitra, Craig T Vollert +19 more
2024Molecular Cancer Therapeutics20 citations Open access
Semantic Scholar
Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients
A. Crispo, L. Augustin, A. Luongo, Claudia Calderaio +25 more
2023Scientific Reports18 citations Open access
Semantic Scholar
Glucocorticoid Receptor and Ovarian Cancer: From Biology to Therapeutic Intervention
R. Buonaiuto, G. Neola, S. Cecere, A. Caltavituro +6 more
2023Biomolecules17 citations Open access
Semantic Scholar
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study.
N. Colombo, A. Gadducci, F. Landoni, D. Lorusso +24 more
2023Gynecologic Oncology16 citations Open access
Semantic Scholar
The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer
M. Cataldo, P. De Placido, D. Esposito, L. Formisano +5 more
2023Frontiers in Oncology16 citations Open access
Semantic Scholar
HER2-Positive Breast Cancer Treatment and Resistance.
J. Veeraraghavan, C. de Angelis, C. Gutierrez, F. Liao +4 more
2025Advances in Experimental Medicine and Biology15 citations
Semantic Scholar
miRNAs in the Box: Potential Diagnostic Role for Extracellular Vesicle-Packaged miRNA-27a and miRNA-128 in Breast Cancer
C. Giordano, F. Accattatis, L. Gelsomino, Piercarlo Del Console +12 more
2023International Journal of Molecular Sciences15 citations Open access
Semantic Scholar
Think “HER2” different: integrative diagnostic approaches for HER2-low breast cancer
C. Marchiò, C. Criscitiello, C. Scatena, Alfredo Santinelli +11 more
2023Pathologica14 citations Open access
Semantic Scholar
ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy
K. Venetis, Giulia Cursano, R. Scafetta, P. B. Giachetti +22 more
2025Breast Cancer Research13 citations Open access
Semantic Scholar
Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer.
L. Licata, M. Dieci, C. de Angelis, C. Marchiò +8 more
2024Cancer Treatment Reviews13 citations Open access
Semantic Scholar
Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type
R. Buonaiuto, G. Neola, A. Caltavituro, Alessandra Longobardi +11 more
2024Frontiers in Oncology11 citations Open access
Semantic Scholar
Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study
M. di Maio, C. Bighin, F. Schettini, T. Ruelle +11 more
2023Breast11 citations Open access
Semantic Scholar
Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: a systematic review and network meta-analysis
R. Buonaiuto, M. Fordellone, A. Caltavituro, M. Cataldo +18 more
2025EClinicalMedicine9 citations Open access
Semantic Scholar
Unlocking the Potential of Immune Checkpoint Inhibitors in HR+/HER2− Breast Cancer: A Systematic Review
G. Di Grazia, Arianna Dri, Angela Grieco, C. Martinelli +10 more
2025Cancers9 citations Open access
Semantic Scholar
Gender minorities in breast cancer – Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients
F. Miglietta, L. Pontolillo, C. de Angelis, R. Caputo +15 more
2024Breast9 citations Open access
Semantic Scholar
Prognostic implications of risk definitions from the monarchE and NATALEE trials
L. Arecco, E. Blondeaux, M. Bruzzone, G. Arpino +16 more
2025Journal of the National Cancer Institute8 citations Open access
Semantic Scholar
Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial
Luca Forlani, L. De Cecco, V. Simeon, B. Paolini +20 more
2023Journal of experimental & clinical cancer research : CR8 citations Open access
Semantic Scholar
Key decision factors in second-line therapy: Expert insights on HR+/HER2-metastatic breast cancer post-CDK4/6 inhibitor progression.
R. Buonaiuto, A. Botticelli, C. Criscitiello, M. Dieci +6 more
2025Cancer Treatment Reviews7 citations Open access
Semantic Scholar
Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trials
E. Blondeaux, Wan-Ling Xie, L. Carmisciano, S. Mura +21 more
2024EClinicalMedicine7 citations Open access
Semantic Scholar
A multiparameter molecular classifier to predict response to neoadjuvant lapatinib plus trastuzumab without chemotherapy in HER2+ breast cancer
J. Veeraraghavan, C. Gutierrez, C. de Angelis, R. Davis +23 more
2023Clinical Cancer Research7 citations Open access
Semantic Scholar
Impaired seroconversion after SARS-CoV-2 mRNA vaccine in patients with thymic epithelial tumors
E. Pietroluongo, P. De Placido, M. Tortora, C. Martinelli +21 more
2023Journal of Thoracic Oncology7 citations Open access
Semantic Scholar
Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial
C. Maurer, E. Agostinetto, L. Ameye, M. Lambertini +12 more
2025Breast Cancer Research and Treatment6 citations Open access
Semantic Scholar
The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): an Italian Delphi consensus report.
F. Miglietta, M. Razeti, A. Caltavituro, Arianna Dri +31 more
2025Critical reviews in oncology/hematology6 citations Open access
Semantic Scholar
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways.
B. Pastò, Giulia Buzzatti, C. Schettino, U. Malapelle +18 more
2024Critical reviews in oncology/hematology6 citations Open access
Semantic Scholar
PIK3CA testing in hormone receptor-positive/HER2-negative metastatic breast cancer: real-world data from Italian molecular pathology laboratories.
F. Pepe, K. Venetis, Giulia Cursano, Chiara Frascarelli +14 more
2024Pharmacogenomics (London)6 citations
Semantic Scholar
Exploring the interplay between Kaposi's sarcoma and SARS‐CoV‐2 infection: A case series and systematic review
E. Pietroluongo, Angelo Luciano, Annarita Peddio, R. Buonaiuto +10 more
2024Journal of Medical Virology5 citations Open access
Semantic Scholar
Influence of ethnicity on cyclin-dependent kinase inhibitor efficacy and toxicity: A systematic review and meta-analysis
R. Buonaiuto, A. Caltavituro, M. Tafuro, Alessandra Longobardi +10 more
2024Breast5 citations Open access
Semantic Scholar
Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation
L. Gerratana, J. Pierga, J. Reuben, A. Davis +30 more
2022The Oncologist5 citations Open access
Semantic Scholar
Association of neoadjuvant chemotherapy dose intensity with pathological complete response and event-free survival in HER2-negative early breast cancer.
R. Buonaiuto, F. Martorana, P. Marino, F. Mangiacotti +12 more
2025European Journal of Cancer4 citations
Semantic Scholar
Insights on the association of anthropometric and metabolic variables with tumor features and genomic risk in luminal early breast cancer: Results of a multicentric prospective study.
P. De Placido, Rossana Di Rienzo, E. Pietroluongo, C. Martinelli +22 more
2025European Journal of Cancer4 citations Open access
Semantic Scholar
Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group.
Lucia Musacchio, E. Palluzzi, M. Di Napoli, R. Lauria +18 more
2024Gynecologic Oncology4 citations
Semantic Scholar
Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study
M. Lambertini, E. Blondeaux, E. Agostinetto, A. Hamy +50 more
2024Obstetrical & Gynecological Survey3 citations Open access
Semantic Scholar
Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2
G. Mazzoli, L. Provenzano, M. Dieci, G. Curigliano +38 more
2026Breast2 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

G. Arpino×19
Invite
G. Arpino — researcher profile on SciRah
M. Giuliano×14
Invite
M. Giuliano — researcher profile on SciRah
L. Del Mastro×12
Invite
L. Del Mastro — researcher profile on SciRah
F. Puglisi×12
Invite
F. Puglisi — researcher profile on SciRah

M. de Laurentiis

×11

Invite

M. de Laurentiis — researcher profile on SciRah

C. Criscitiello×10

Invite

C. Criscitiello — researcher profile on SciRah

Invite

R. Caputo — researcher profile on SciRah

P. De Placido×9

Invite

P. De Placido — researcher profile on SciRah

R. Buonaiuto×9

Invite

R. Buonaiuto — researcher profile on SciRah

A. Caltavituro×9

Invite

A. Caltavituro — researcher profile on SciRah

Invite

M. Dieci — researcher profile on SciRah

Invite

M. Giuliano — researcher profile on SciRah